Journal article
Colchicine in Cardiovascular Disease: In-Depth Review
SG Deftereos, FJ Beerkens, B Shah, G Giannopoulos, DA Vrachatis, SG Giotaki, G Siasos, J Nicolas, C Arnott, S Patel, M Parsons, JC Tardif, JC Kovacic, GD Dangas
Circulation | LIPPINCOTT WILLIAMS & WILKINS | Published : 2022
Abstract
Inflammation plays a prominent role in the development of atherosclerosis and other cardiovascular diseases, and anti-inflammatory agents may improve cardiovascular outcomes. For years, colchicine has been used as a safe and well-tolerated agent in diseases such as gout and familial Mediterranean fever. The widely available therapeutic has several anti-inflammatory effects, however, that have proven effective in a broad spectrum of cardiovascular diseases as well. It is considered standard-of-care therapy for pericarditis, and several clinical trials have evaluated its role in postoperative and postablation atrial fibrillation, postpericardiotomy syndrome, coronary artery disease, percutaneo..
View full abstractRelated Projects (1)
Grants
Awarded by National Institutes of Health
Funding Acknowledgements
C. A. holds a National Health and Medical Research Council/Medical Research Future Fund Priority Investigator Grant and an New South Wales Health Early-Mid Career Research Grant (both of which are not for colchicine studies). S.P. holds the following Australian National Health and Medical Research Council/Medical Research Future Fund colchicine grants: COLCARDIO-ACS GA65779, CASPER GA82107, and IMPACT-ICO GA85492. These studies are supported by Aspen Pharmacare Australia, who are providing drug and placebo. S.P. also holds a New South Wales Cardiovascular Health Fellowship to support colchicine research. M. P. receives funding from the National Health and Medical Research Council Program Grant in Stroke (ID 1113352). J.C.K. received funding from the National Institutes of Health (R01HL130423, R01HL135093, R01HL148167-01A1) and a New South Wales health grant (RG194194).